|
|
||||||||

* Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, Milan, Italy; and
Department of Medicine, Division of Rheumatic and Autoimmune Diseases, and Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455
Proliferation of Ag-specific T cells is central to the development of protective immunity. The concomitant stimulation of the TCR and CD28 programs resting T cells to IL-2-driven clonal expansion. We report that a prolonged occupancy of the TCR and CD28 bypasses the need for autocrine IL-2 secretion and sustains IL-2-independent lymphocyte proliferation. In contrast, a short engagement of the TCR and CD28 only drives the expansion of cells capable of IL-2 production. TCR/CD28- and IL-2-driven proliferation revealed a different requirement for PI3K and for the mammalian target of rapamycin (mTOR). Thus, both PI3K and mTOR activities were needed for T cells to proliferate to TCR/CD28-initiated stimuli and for optimal cyclin E expression. In contrast, either PI3K or mTOR were sufficient for IL-2-driven cell proliferation as they independently mediated cyclin E induction. Interestingly, rapamycin delayed cell cycle entry of IL-2-sufficient T cells, but did not prevent their expansion. Together, our findings indicate that the TCR, CD28, and IL-2 independently control T cell proliferation via distinct signaling pathways involving PI3K and mTOR. These data suggest that Ag persistence and the availability of costimulatory signals and of autocrine and paracrine growth factors individually shape T lymphocyte expansion in vivo.
This article has been cited by other articles:
![]() |
J. Kang, S. J. Huddleston, J. M. Fraser, and A. Khoruts De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR J. Leukoc. Biol., May 1, 2008; 83(5): 1230 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mariotti, J. Foley, U. Jung, T. Borenstein, N. Kantardzic, S. Han, J. T. Hanson, E. Wong, N. Buxhoeveden, J. B. Trepel, et al. Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection J. Immunol., January 1, 2008; 180(1): 89 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Yarke, S. L. Dalheimer, N. Zhang, D. M. Catron, M. K. Jenkins, and D. L. Mueller Proliferating CD4+ T Cells Undergo Immediate Growth Arrest upon Cessation of TCR Signaling In Vivo J. Immunol., January 1, 2008; 180(1): 156 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zheng, S. L. Collins, M. A. Lutz, A. N. Allen, T. P. Kole, P. E. Zarek, and J. D. Powell A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy J. Immunol., February 15, 2007; 178(4): 2163 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kolly, M. A. Thiel, T. Herrmann, and A. Pluckthun Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction Protein Eng. Des. Sel., February 8, 2007; (2007) gzl058v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-W. Shui, M. C.-T. Hu, and T.-H. Tan Conditional Knockout Mice Reveal an Essential Role of Protein Phosphatase 4 in Thymocyte Development and Pre-T-Cell Receptor Signaling Mol. Cell. Biol., January 1, 2007; 27(1): 79 - 91. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |